Literature DB >> 21457222

Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics.

Atsushi Yonezawa1, Ken-ichi Inui.   

Abstract

The renal organic cation transport system mediates the tubular secretion of cationic compounds including drugs, toxins and endogenous metabolites into urine. It consists of a membrane potential-dependent organic cation transporter at the basolateral membrane and an H(+) /organic cation antiporter at the brush-border membrane. In 2005, human multidrug and toxin extrusion MATE1/SLC47A1 was identified as a mammalian homologue of bacterial NorM. Thereafter, human MATE2-K/SLC47A2 and rodent MATE were found. Functional characterization revealed that MATE1 and MATE2-K were H(+) /organic cation antiporter, mediating the renal tubular secretion of cationic drugs in cooperation with the basolateral organic cation transporter OCT2. Recently, substrate specificity, transcription mechanisms, structure, polymorphisms, in vivo contributions and clinical outcomes on MATE have been investigated intensively. In this review, we summarize recent findings on MATE1/SLC47A1 and MATE2-K/SLC47A2 and discuss the importance of these transporters to the pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics of cationic drugs.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21457222      PMCID: PMC3246706          DOI: 10.1111/j.1476-5381.2011.01394.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  66 in total

1.  OCT2 and MATE1 provide bidirectional agmatine transport.

Authors:  Tate N Winter; William F Elmquist; Carolyn A Fairbanks
Journal:  Mol Pharm       Date:  2010-12-03       Impact factor: 4.939

2.  H+ gradient-dependent transport of aminocephalosporins in rat renal brush border membrane vesicles: role of H+/organic cation antiport system.

Authors:  K Inui; M Takano; T Okano; R Hori
Journal:  J Pharmacol Exp Ther       Date:  1985-04       Impact factor: 4.030

Review 3.  Cellular and molecular aspects of drug transport in the kidney.

Authors:  K I Inui; S Masuda; H Saito
Journal:  Kidney Int       Date:  2000-09       Impact factor: 10.612

4.  Effects of metabolic acidosis on expression levels of renal drug transporters.

Authors:  Arong Gaowa; Hideyuki Motohashi; Toshiya Katsura; Ken-ichi Inui
Journal:  Pharm Res       Date:  2010-12-15       Impact factor: 4.200

5.  Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations.

Authors:  J König; O Zolk; K Singer; C Hoffmann; M F Fromm
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

6.  Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents.

Authors:  Atsushi Yonezawa; Ken-Ichi Inui
Journal:  Biochem Pharmacol       Date:  2010-12-07       Impact factor: 5.858

7.  Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations.

Authors:  Johan W Jonker; Els Wagenaar; Sven Van Eijl; Alfred H Schinkel
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

8.  Carrier-mediated transport systems of tetraethylammonium in rat renal brush-border and basolateral membrane vesicles.

Authors:  M Takano; K Inui; T Okano; H Saito; R Hori
Journal:  Biochim Biophys Acta       Date:  1984-06-13

9.  Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs.

Authors:  A Somogyi; A McLean; B Heinzow
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Cimetidine inhibits renal procainamide clearance.

Authors:  C D Christian; C G Meredith; K V Speeg
Journal:  Clin Pharmacol Ther       Date:  1984-08       Impact factor: 6.875

View more
  53 in total

1.  Transporters are an under-developed therapeutic target. Discuss.

Authors:  Steve Alexander
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

Review 2.  Advances in predictive in vitro models of drug-induced nephrotoxicity.

Authors:  Joanne Y-C Soo; Jitske Jansen; Rosalinde Masereeuw; Melissa H Little
Journal:  Nat Rev Nephrol       Date:  2018-06       Impact factor: 28.314

3.  Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers.

Authors:  Sung Kweon Cho; Choon Ok Kim; Eun Seok Park; Jae-Yong Chung
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

4.  The N-terminal domain of an archaeal multidrug and toxin extrusion (MATE) transporter mediates proton coupling required for prokaryotic drug resistance.

Authors:  Kevin L Jagessar; Hassane S Mchaourab; Derek P Claxton
Journal:  J Biol Chem       Date:  2019-07-09       Impact factor: 5.157

5.  Sodium and proton coupling in the conformational cycle of a MATE antiporter from Vibrio cholerae.

Authors:  Derek P Claxton; Kevin L Jagessar; P Ryan Steed; Richard A Stein; Hassane S Mchaourab
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-18       Impact factor: 11.205

Review 6.  Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney.

Authors:  Hideyuki Motohashi; Ken-ichi Inui
Journal:  AAPS J       Date:  2013-02-22       Impact factor: 4.009

7.  The Concise Guide to PHARMACOLOGY 2013/14: transporters.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

8.  Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation.

Authors:  Jia Yin; Haichuan Duan; Joanne Wang
Journal:  J Pharmacol Exp Ther       Date:  2016-10-06       Impact factor: 4.030

9.  Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.

Authors:  Matthias B Wittwer; Arik A Zur; Natalia Khuri; Yasuto Kido; Alan Kosaka; Xuexiang Zhang; Kari M Morrissey; Andrej Sali; Yong Huang; Kathleen M Giacomini
Journal:  J Med Chem       Date:  2013-01-22       Impact factor: 7.446

10.  Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.

Authors:  Matthew L Rizk; Robert Houle; Grace Hoyee Chan; Mike Hafey; Elizabeth G Rhee; Xiaoyan Chu
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.